WO2023155568A1 - 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途 - Google Patents

一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途 Download PDF

Info

Publication number
WO2023155568A1
WO2023155568A1 PCT/CN2022/138603 CN2022138603W WO2023155568A1 WO 2023155568 A1 WO2023155568 A1 WO 2023155568A1 CN 2022138603 W CN2022138603 W CN 2022138603W WO 2023155568 A1 WO2023155568 A1 WO 2023155568A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver cancer
sorafenib
liver
strain
group
Prior art date
Application number
PCT/CN2022/138603
Other languages
English (en)
French (fr)
Inventor
刘星吟
王静静
季国忠
Original Assignee
南京医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京医科大学 filed Critical 南京医科大学
Publication of WO2023155568A1 publication Critical patent/WO2023155568A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the technical field of microorganisms, and relates to Lactobacillus paracasei L511 capable of inhibiting the growth of liver cancer tumors and its application.
  • Hepatocellular carcinoma accounts for 90% of the pathological types of primary liver cancer and is the second leading cause of death in male malignant tumors. It is increasing year by year, and the situation is more serious.
  • the treatment methods for stage liver cancer mainly include surgery, drugs, radiotherapy and chemotherapy, etc., but the curative effect is poor. Liver cancer progresses rapidly and is highly metastatic, which makes surgical treatment difficult. Even if surgical resection is possible, the five-year recurrence rate after surgery is as high as 70%. , the five-year survival rate is only 10%. Therefore, there is an urgent need for more effective treatment strategies to prolong the survival time and improve the quality of life of patients with advanced liver cancer.
  • sorafenib As a targeted drug, has certain survival benefits for patients with advanced liver cancer in different countries and regions and with different liver disease backgrounds.
  • Rafenib is recommended as a first-line treatment for liver cancer in clinical treatment.
  • the objective response rate of sorafenib is only 5%, and the side effects of sorafenib are strong, including diarrhea, weight loss, hand-foot syndrome, rash, myocardial ischemia and hypertension, etc. Therefore, improving the efficacy of sorafenib and reducing its side effects are of great significance to the clinical use of sorafenib.
  • CN105535650A discloses a probiotic composition with anti-tumor function (subcutaneous transplantation of liver cancer cell lines).
  • the strains of probiotics have not been identified, and the formula does not have universal applicability due to the significant differences among different strains of the same probiotics in terms of probiotic function; similarly, the strains of probiotics in CN10468665 7A and CN101711775A have not been identified, and The function of the components of the fermented product is not clear.
  • the present application provides Lactobacillus paracasei and its application.
  • Lactobacillus paracasei LSC-L511 was preserved in the General Microbiology Center CGMCC of the China Microbiological Culture Collection Management Committee on January 14, 2022, and the preservation address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing Institute of Microbiology, Chinese Academy of Sciences, the deposit number is CGMCC NO.24309.
  • Lactobacillus paracasei L511 described in the present invention in the preparation of medicine for treating liver cancer.
  • the bacterial agent prepared by Lactobacillus paracasei L511 of the present invention prepared by Lactobacillus paracasei L511 of the present invention.
  • Lactobacillus paracasei L511 combined with sorafenib in the preparation of medicine for treating liver cancer according to the present invention.
  • the single bacterium of this strain has a strong ability to regulate the polarization of macrophages, can significantly inhibit the progression of liver cancer, can enhance the therapeutic effect of sorafenib on liver cancer by inducing ferroptosis of liver cancer cells, and can also relieve colonic inflammation , Improve the structure of intestinal flora and the level of short-chain fatty acids and other functions and uses.
  • FIG 1 Liver conditions of mice in each group after sacrifice
  • FIG. 1 Liver weight (A), liver index (B), number of liver nodules (C), spleen weight (D), and spleen index (E) of mice in each group
  • FIG. 3 HE staining of mouse liver tissue in each group: A is the control group B is the strain intervention group of the present invention C is the Sorafenib treatment group alone D is the combined treatment group
  • FIG. 6 each group of mouse colon tissue section HE staining: A is liver cancer model control group B is Sorafenib alone treatment group C is Sorafenib combined treatment group with bacterial strains of the present invention
  • Figure 8 Expression of tight junction protein occludin in mouse intestinal tissues of each group
  • FIG. 10 Expressions of total iron (A), ferrous iron (B) and ferric iron (C) in the liver tissues of mice in each group
  • Figure 11 Composition of mouse intestinal flora (phylum level)
  • Lactobacillus paracasei L511 Isolation and screening of Lactobacillus paracasei L511: (1) Collect yoghurt samples, spread the samples on MRS solid plates after gradient dilution, and culture for 24-48 hours; (2) Select a single colony that conforms to the basic shape of lactic acid bacteria to streak the plate Purify, screen and isolate lactic acid bacteria; (3) Culture the above-mentioned single colony in liquid MRS culture medium for 24 hours, extract bacterial DNA, perform PCR, and send it to a sequencing company for 16s identification.
  • Lactobacillus paracasei L511 Gram-positive bacillus, oxidase (-), catalase (-), glycerol (-), inositol (-), inulin (-), erythrinol (-) , mannitol (+), raffinose (-), melezitose (-), sorbitol (+), D-arabinose (-), L-arabinose (-), a-methyl_D- Mannoside (-), starch (-), glycogen (-), a-methyl_D-glucoside (-), D-ribose (+), D-xylose (-), N-acetyl- Glucosamine (+), Xylitol (-), Gentiobiose (-), Laetrile (+), L-Xylose (-), Adonol (+), Arbutin (+) , D-turanose (+), D-lyxose (-), escin (+
  • MRS medium 10.0 grams of casein peptone, 10.0 grams of beef extract, 5.0 grams of yeast extract, 5.0 grams of glucose, 5.0 grams of sodium acetate, 2.0 grams of diamine citrate, 1.0 grams of Tween 80, dipotassium hydrogen phosphate 2.0 grams, 0.2 grams of magnesium sulfate heptahydrate, 0.05 grams of manganese sulfate heptahydrate, 20.0 grams of calcium carbonate, 1.0 liter of distilled water, pH 6.8.
  • the bacteria were planted in the MRS liquid medium, cultured in an anaerobic incubator at 37°C, and the bacterial concentration was determined according to the bacterial absorbance (OD600) and bacterial plate count.
  • Cultivate to the end of the logarithmic phase take out the bacterial solution, centrifuge at 12000rpm/min for 15-20min, wash with PBS 2-3 times, adjust the concentration to 1x10 9 CFU/ml with PBS for intragastric administration to mice.
  • liver cancer model control group Forty 15-day-old male C57BL/6 mice were taken out and randomly divided into 4 groups: liver cancer model control group, this strain intervention group, sorafenib treatment group and combined treatment group, with 10 mice in each group.
  • Liver cancer chemical model mice were injected intraperitoneally with DEN reagent at 25 mg/kg according to body weight at 14 days old, and CCL4 reagent with a concentration of 20% was injected intraperitoneally once a week from the fourth week of birth, at 5ul/g, for 16 consecutive weeks.
  • mice in the chemical model control group and the sorafenib group were fed with 200ulPBS every two days from the 14th week after birth, and the mice in the intervention group of this strain and the combined treatment group were fed with 200ulPBS every two days since the 14th week after birth.
  • Feed 200ul of this strain suspension prepared in PBS with a concentration of 10 9 CFU/mL for two days, and the Sorafenib group and the combined treatment group were fed with Sorafenib from the 16th week, 30mg/Kg, for 15 consecutive days. sky.
  • the serum, liver, colorectum, and spleen of the mice were collected. Among them, the number of nodules on the liver surface of the liver cancer chemical model mice was calculated, and the weight of the liver, the length of the colorectum and the weight of the spleen of the mice were counted. At the same time, colon tissue and liver were taken for paraffin section operation and routine H&E staining.
  • the intervention group of the strain of the present invention can significantly reduce the number of tumors, liver weight, liver index and spleen index are significantly reduced; Compared with the control group, the number of tumors in the combined treatment group was also significantly reduced, and the liver weight, liver index, and spleen index were also significantly reduced.
  • the H&E staining results are shown in Figure 3. It can be clearly seen from the slices that the liver cancer control group mice have serious lesions. Compared with the control group mice, the tumor cell infiltration was significantly improved after the bacterial strain of the present invention was administered into the stomach. Compared with the fenib alone treatment group, the tumor cell infiltration in the combined treatment group was also significantly improved.
  • Example 4 The regulatory effect of the strains of the present invention on related inflammatory factors in the serum of liver cancer mice
  • the blood of the liver cancer chemical model mice in Example 3 was collected, centrifuged at room temperature, and the supernatant was taken to obtain mouse serum, and the contents of IL-12 and other cytokines in the serum were measured by Elisa.
  • the results are as shown in Figure 4, IL-12, IL-18, TNF- ⁇ , IL-1a levels in the serum of the mice in the bacterial strain intervention group of the present invention were significantly higher than those of the liver cancer control group, and compared with those of the Sorafenib treatment group alone. Compared with that, the levels of IL-12, IL-18, TNF- ⁇ , and IL-1a in the serum of mice in the combined treatment group were also significantly increased.
  • Example 5 The strain of the present invention can reduce the side effects of intestinal inflammation caused by Sorafenib treatment
  • Collect the colorectum of the liver cancer chemical model mice in Example 3 measure the colorectum length of the liver cancer model control group, Sorafenib alone treatment group and Sorafenib bacterial strains of the present invention combined treatment group, as shown in Figure 5, Compared with the sorafenib treatment group, the intestinal tract of the mice in the combined treatment group showed a tendency to grow.
  • H&E staining result is as shown in Figure 6, as can be clearly seen from the section, compared with liver cancer model control group, Sorafenib treatment group alone, after bacterial strain of the present invention is gavaged, inflammatory cell infiltration reduces, and glandular structure has Restored, symptom obviously alleviated, according to pathological scoring standard by two people respectively independent scoring mean value is got statistics, and pathological scoring result is as shown in Figure 7, and after bacterial strain gavage of the present invention, pathological scoring reduces.
  • Example 6 This strain induces the polarization of liver macrophages in mice with liver cancer to regulate the tumor microenvironment
  • Example 7 The strain of the present invention promotes ferroptosis of liver cancer cells
  • the mouse liver tissue in Example 3 was taken, and the change of iron in the tissue was detected by a kit.
  • the accumulation of iron ions, ferrous ions and total iron in the tumor tissue of the combined treatment group increased, which promoted the ferroptosis of liver cancer cells and inhibited the progression of liver cancer .
  • Example 8 The repairing effect of this bacterial strain on intestinal flora imbalance in mice with liver cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供了一种具有抑制肝癌肿瘤生长的副干酪乳杆菌(Lactobacillus paracasei)L511及其用途。该菌株于2022年1月14日保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC NO.24309。该菌株单菌具有调节巨噬细胞极化的能力，可抑制肝癌的进展，能够通过诱导肝癌细胞铁死亡来增强索拉非尼对肝癌的治疗效果，并且还有缓解结肠炎症、改善肠道菌群结构及短链脂肪酸水平的功能和用途。

Description

一种具有抑制肝癌肿瘤生长的副干酪乳杆菌L511及其用途 技术领域
本发明涉及微生物技术领域，涉及一种具有抑制肝癌肿瘤生长的副干酪乳杆菌L511及其用途。
背景技术
肝细胞癌(Hepatocellular carcinoma,HCC)占原发性肝癌病理类型的90％，是男性恶性肿瘤的第二大死因，在我国，每年增加的肝癌患者约占全球新增病例的一半，死亡率也在逐年升高，形势较为严峻。阶段肝癌的治疗方法主要包括手术、药物、放化疗等，但疗效较差，肝癌进展迅速、转移性强导致手术治疗很难实施，即使可以采取手术切除，术后五年的复发率高达70％，五年生存率仅10％，因此，临床迫切需要更有效的治疗策略来延长中晚期肝癌患者的生存时间并改善其生存质量。近年来，大量研究表明肠道微生态失衡与肝癌发生发展密切相关，因此维持肠道菌群稳定对防治肝癌具有重要的意义。肠道和肝脏通过胆汁酸肠肝循环及门静脉循环紧密地联系起来，因此益生菌在治疗肝脏疾病中发挥重要作用。
根据《原发性肝癌诊疗规范(2019年版)》推荐，索拉非尼(sorafenib)作为一种靶向药对于不同国家地区、不同肝病背景的晚期肝癌病人都具有一定的生存获益，因此索拉非尼被推荐作为肝癌的一线治疗用药应用于临床治疗。但根据临床病例统计分析，索拉非尼的客观缓解率仅有5％，且索拉非尼副作用强烈，包括腹泻、体质量下降、手足综合征、皮疹、心肌缺血以及高血压等给，因此提高索拉非尼的疗效、减轻其带来的副作用对临床使用索拉非尼意义重大。有文献报道微生物源性的葡萄球菌超级抗原样蛋白6(SSL6)增强肝细胞癌(HCC)细胞对索拉非尼(SFN)敏感性的潜在机制，为索拉非尼与肠道微生物联合应用提供了理论依据。
在目前已经公开的文献与专利或专利申请中，有少量针对益生菌或益生菌复配、发酵产物抑制肿瘤的专利，但并无真正涉及具有抑制肝癌发生功能的明确益生菌菌株。例如，CN105535650A公开了一种具有抗肿瘤(肝癌细胞株皮下移植)功能的益生菌组合物，组合物涉及到多种益生菌及中药成分，但未明确其中各株 菌的肿瘤抑制功能，且所有益生菌均未明确到株，由于在益生功能上同种益生菌不同菌株间差异显著，故该配方并不具有普适性；同样，CN10468665 7A和CN101711775A中的益生菌也未明确到株，且发酵物成分功能不明确。
发明内容
针对现有技术存在的上述问题，本申请提供了一种副干酪乳杆菌及其用途。
本发明的目的可通过以下技术方案实现：
一种副干酪乳杆菌(Lactobacillus paracasei)LSC-L511，于2022年1月14日保藏于中国微生物菌种保藏管理委员会普通微生物中心CGMCC，保藏地址为北京市朝阳区北辰西路1号院3号中国科学院微生物研究所，保藏编号为CGMCC NO.24309。
本发明所述的副干酪乳杆菌L511在制备治疗肝癌的药物中的应用。
由本发明所述的副干酪乳杆菌L511制备的菌剂。
本发明所述的菌剂在制备治疗肝癌的药物中的应用。
本发明所述的副干酪乳杆菌L511联合索拉非尼在制备治疗肝癌的药物中的应用。
本发明所述的副干酪乳杆菌L511制备的菌剂联合索拉非尼在制备治疗肝癌的药物中的应用。
有益效果：
本菌株单菌即具有很强的调节巨噬细胞极化的能力，可显著抑制肝癌的进展，能够通过诱导肝癌细胞铁死亡来增强索拉非尼对肝癌的治疗效果，并且还有缓解结肠炎症，改善肠道菌群结构及短链脂肪酸水平等多种功能和用途。
附图说明
图1：各组小鼠处死后肝脏情况
图2：各组小鼠肝脏重量(A)、肝脏指数(B)、肝脏结节数(C)、脾脏重量(D)、脾脏指数(E)
图3：各组小鼠肝脏组织HE染色：A为对照组B为本发明菌株干预组C为索拉非尼单独治疗组D为联合治疗组
图4：各组小鼠血清炎症因子表达情况
图5:各组小鼠结直肠长度
图6:各组小鼠结肠组织切片HE染色：A为肝癌模型对照组B为索拉非尼单独治疗组C为索拉非尼与本发明菌株联合治疗组
图7：各组小鼠结直肠组织病理评分
图8：各组小鼠肠组织紧密连接蛋白occludin表达情况
图9：通过流式细胞术检测肝脏组织中M1型巨噬细胞及M2巨噬细胞极化情况
图10：各组小鼠肝脏组织中总铁(A)、二价铁离子(B)、三价铁离子(C)表达情况
图11：小鼠肠道菌群组成(门水平)
具体实施方式
实施例1
副干酪乳杆菌L511的分离筛选：(l)收集酸奶样本，将样品进行梯度稀释后涂布于MRS固体平板上，培养24-48h；(2)选取符合乳酸菌基本形态的单菌落进行平板划线纯化，筛选分离出乳酸菌；(3)将上述单菌落培养于液体MRS培养液中培养24h后提取细菌DNA，进行PCR，并送测序公司进行16s鉴定。
副干酪乳杆菌L511的生理生化特征：革兰阳性杆菌，氧化酶(-)，接触酶(-)，甘油(-)，肌醇(-)，菊糖(-)，赤癣醇(-)，甘露醇(+)，棉子糖(-)，松三糖(-)，山梨醇(+)，D-阿拉伯糖(-)，L-阿拉伯糖(-)，a-甲基_D-甘露糖甙(-)，淀粉(-)，糖原(-)，a-甲基_D-葡萄糖甙(-)，D-核糖(+)，D-木糖(-)，N-乙酰-葡糖胺(+)，木糖醇(-)，龙胆二糖(-)，苦杏仁甙(+)，L-木糖(-)，阿东醇(+)，熊果苷(+)，D-松二糖(+)，D-来苏糖(-)，七叶灵(+)，β-甲基 -D-木糖甙(-)，D-半乳糖(+)，水杨苷(+)，D-塔格糖(+)，D-岩藻糖(-)，麦芽糖(+)，D-果糖(+)，麦芽糖(+)，L-岩藻糖(-)，D-甘露糖(+)，乳糖(+)，D-阿拉伯糖醇(-)，L-山梨糖(-)，蜜二糖(-)，L-阿拉伯糖醇(-)，L-鼠李糖(-)，蔗糖(-)，卫茅醇(-)，海藻糖(+)，葡萄糖酸盐(-)，2-酮基-葡萄糖酸盐(-)。
鉴定为副干酪乳杆菌的依据：16S rRNA基因序列测定如SEQ ID NO.1所示。
实施例2
配制MRS培养基：称酪蛋白胨10.0克，牛肉浸取物10.0克，酵母提取液5.0克，葡萄糖5.0克，乙酸钠5.0克，柠檬酸二胺2.0克，吐温80 1.0克，磷酸氢二钾2.0克，七水硫酸镁0.2克，七水硫酸锰0.05克，碳酸钙20.0克，蒸馏水1.0升，pH 6.8。按1：500比例将菌种种于MRS液体培养基中，于37℃厌氧培养箱培养，根据细菌吸光度(OD600)及细菌平板计数，确定细菌浓度。培养至对数期末期，取出菌液，12000rpm/min离心15-20min，用PBS洗涤2-3次后，用PBS将浓度调整至1x10 9CFU/ml用于小鼠灌胃。
实施例3副干酪乳杆菌L511对小鼠肝癌的缓解作用
取出生15天的雄性C57BL/6小鼠40只，随机分为4组：肝癌模型对照组、本菌株干预组，索拉非尼治疗组及联合治疗组，每组含小鼠10只。
肝癌化学模型小鼠出生14天，按体重腹腔注射DEN试剂，25mg/kg，出生第四周开始每周腹腔注射浓度为20％的CCL4试剂一次，5ul/g，连续注射16周。
造模过程中，化学模型对照组小鼠及索拉非尼组小鼠自出生后第14周开始每两天喂200ulPBS，本菌株干预组及联合治疗组小鼠自出生后第14周开始每两天喂200ul浓度为10 9CFU/mL的本菌株悬液(PBS配制)，索拉非尼组及联合治疗组自第16周开始灌胃索拉非尼，30mg/Kg，连续灌胃15天。
造模结束后，取小鼠的血清、肝脏、结直肠、脾脏。其中，计算肝癌化学模型小鼠肝脏表面结节个数，统计小鼠肝脏重量、结直肠长度、脾脏重量。同时取结肠组织、肝脏进行石蜡切片操作并进行常规H&E染色。
结果如图1-2所示，与肝癌对照组相比，本发明菌株灌胃的干预组可以显著 减少肿瘤的数量，肝脏重量、肝脏指数以及脾脏指数都明显降低；与索拉非尼单独治疗组相比，联合治疗组小鼠肿瘤数量也明显减少，肝脏重量、肝脏指数以及脾脏指数也都明显降低。H&E染色结果如图3所示，从切片中可以明显看出，肝癌对照组小鼠病变严重，相比于对照组小鼠，经本发明菌株灌胃后，肿瘤细胞浸润明显改善，与索拉非尼单独治疗组相比，联合治疗组小鼠肿瘤细胞浸润也明显改善。
实施例4本发明菌株对肝癌小鼠血清中相关炎症因子的调节作用
收集实施例3中的肝癌化学模型小鼠的血液，常温离心，取上清得到小鼠血清，使用Elisa测定血清中IL-12等细胞因子的含量。结果如图4所示，本发明菌株干预组小鼠血清中IL-12、IL-18、TNF-α、IL-1a水平较对肝癌照组显著升高，与索拉非尼单独治疗组相比，联合治疗组小鼠血清中IL-12、IL-18、TNF-α、IL-1a水平也显著升高。
实施例5本发明菌株可减轻索拉非尼治疗带来的肠道炎症副作用
收集实施例3中肝癌化学模型小鼠的结直肠，测量肝癌模型对照组、索拉非尼单独治疗组及索拉非尼本发明菌株联合治疗组小鼠结直肠长度，如图5所示，相较于索拉非尼治疗组，联合治疗组小鼠肠道有增长趋势。
H&E染色结果如图6所示，从切片中可以明显看出，相比于肝癌模型对照组、索拉非尼单独治疗组，经本发明菌株灌胃后，炎症细胞浸润减少，腺体结构有所恢复，症状明显减轻，根据病理评分标准由两人分别独立评分后取均值进行统计，病理评分结果如图7所示，经本发明菌株灌胃后，病理评分降低。
取实施例3中小鼠结直肠组织0.5cm，制作切片，经过脱蜡、抗原修复、封闭、抗体孵育等步骤进行免疫荧光染色，结果如图8所示，联合治疗组肠道紧密连接蛋白Occludin表达较其他两组明显增加。
组织学病理评分标准
Figure PCTCN2022138603-appb-000001
Figure PCTCN2022138603-appb-000002
实施例6本菌株诱导肝癌小鼠肝脏巨噬细胞极化来调控肿瘤微环境
取实施例3中各组小鼠肝脏组织，经过胶原酶消化后提取单核细胞，通过流式细胞术检测肝癌模型小鼠肝脏中M1、M2型巨噬细胞比例来探究本菌株对巨噬细胞极化的调控作用。结果如图9所示，本菌株可促进肝脏巨噬细胞向M1极化，抑制其向M2极化，进而发挥抑制肿瘤作用。
实施例7本发明菌株促进肝癌细胞铁死亡
取实施例3中小鼠肝脏组织，通过试剂盒检测组织中铁的变化。如图10，相较于肝癌模型对照组、索拉非尼单独治疗组，联合治疗组肿瘤组织内铁离子、亚铁离子及总铁累积增加，促进了肝癌细胞的铁死亡，抑制肝癌的进展。
实施例8本菌株对肝癌小鼠肠道菌群失调的修复作用
取肝癌模型对照组(HCC)、本菌株干预组(LSC)小鼠0.1g粪便，提取参照试剂盒(FastDNA Spin Kit for Soil)说明书，略作改动，具体方法如下所示。将约0.1g粪便加至Lysing Matrix E管中，并加入978μL Sodium Phosphate Buffer和122μL MT Buffer，然后于室温下静置30min；使用Fastprep，设置速度为6.0，设置时间为40，进行破碎；于4℃下以14000×g离心10min后取上清，加入250μL PPS，颠倒混匀；于4℃下以14000×g离心10min，取上清并加入1mL Binding Matrix Suspension，颠倒混匀后，于室温下静置3min，并弃去650μL上清，振荡重悬后，取650μL悬浊液至SPIN Fitter，于4℃下以14000×g离心2min，弃去托管中的液体并重复一次上述步骤；加入500μL SEWS-M(使用前加入100mL无水乙醇，并充分振荡混匀)，于4℃下以14000×g离心1min，弃去托管中的液体，再次以相同条件离心；使用新的集液管，并于室温下静置5min；加入50μL DES，放置在55℃的金属浴中保温5min；然后于 4℃下以14000×g离心1min，集液管中即为DNA溶液，将得到的DNA溶液送至二代测序仪测序并分析。结果如图11所示，本菌株的摄入能够显著的增加模型小鼠肠道内厚壁菌门及疣微菌门的丰度。

Claims (6)

  1. 一株具有抑制肝癌肿瘤生长的干酪乳杆菌(Lactobacillus casei)L511，于2022年1月14日保藏于中国微生物菌种保藏管理委员会普通微生物中心CGMCC，保藏地址为北京市朝阳区北辰西路1号院3号中国科学院微生物研究所，保藏编号为CGMCC NO.24309。
  2. 权利要求1所述的干酪乳杆菌L511在制备治疗肝癌的药物中的应用。
  3. 由权利要求1所述的干酪乳杆菌L511制备的菌剂。
  4. 权利要求3所述的菌剂在制备治疗肝癌的药物中的应用。
  5. 权利要求1所述的干酪乳杆菌L511联合索拉非尼在制备治疗肝癌的药物中的应用。
  6. 权利要求3所述的干酪乳杆菌L511制备的菌剂联合索拉非尼在制备治疗肝癌的药物中的应用。
PCT/CN2022/138603 2022-02-21 2022-12-13 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途 WO2023155568A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210158701.2 2022-02-21
CN202210158701.2A CN114540227B (zh) 2022-02-21 2022-02-21 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途

Publications (1)

Publication Number Publication Date
WO2023155568A1 true WO2023155568A1 (zh) 2023-08-24

Family

ID=81676553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/138603 WO2023155568A1 (zh) 2022-02-21 2022-12-13 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途

Country Status (2)

Country Link
CN (1) CN114540227B (zh)
WO (1) WO2023155568A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114540227B (zh) * 2022-02-21 2023-06-23 南京医科大学 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658226A (zh) * 2013-08-16 2016-06-08 香港大学 使用益生菌治疗癌症的方法和组合物
US20200206282A1 (en) * 2018-12-31 2020-07-02 Md Healthcare Inc. Extracellular vesicles derived from lactobacillus paracasei and use thereof
CN111705086A (zh) * 2020-07-03 2020-09-25 兰州大学 一种抗消化系统肿瘤的浆水无细胞培养液
CN114540227A (zh) * 2022-02-21 2022-05-27 南京医科大学 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169179A1 (en) * 2018-02-28 2019-09-06 Shafer Kim Augmenting efficacy of cancer therapies using probiotic based compositions
KR102098067B1 (ko) * 2018-12-31 2020-04-07 주식회사 엠디헬스케어 락토바실러스 파라카제이 유래 소포 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658226A (zh) * 2013-08-16 2016-06-08 香港大学 使用益生菌治疗癌症的方法和组合物
US20200206282A1 (en) * 2018-12-31 2020-07-02 Md Healthcare Inc. Extracellular vesicles derived from lactobacillus paracasei and use thereof
CN111705086A (zh) * 2020-07-03 2020-09-25 兰州大学 一种抗消化系统肿瘤的浆水无细胞培养液
CN114540227A (zh) * 2022-02-21 2022-05-27 南京医科大学 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAO, FANGFANG ET AL.: "Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease", ARCHIVES OF MEDICAL SCIENCE, vol. 15, no. 5, 12 July 2019 (2019-07-12), pages 1336 - 1343, XP093085168, ISSN: 1734-1922, DOI: 10.5114/aoms.2019.86611 *

Also Published As

Publication number Publication date
CN114540227A (zh) 2022-05-27
CN114540227B (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
Yuan et al. Different frequencies of Porphyromonas gingivalis infection in cancers of the upper digestive tract
TWI791190B (zh) 具有預防或治療癌症的效果的新穎菌株
CN107619811A (zh) 植物乳杆菌ccfm200菌株与应用
CN110144310B (zh) 一株具有缓解肠炎和促进肠道发育作用的枯草芽孢杆菌和应用
US11554146B2 (en) Lactic acid bacteria and use thereof
CN114107121B (zh) 一种凝结芽孢杆菌及其在酒精性肝病的治疗中的应用
CN114847483B (zh) 长双歧杆菌bl21及包含其的菌剂在制备预防、缓解或治疗结直肠癌的产品中的应用
WO2023155568A1 (zh) 一种具有抑制肝癌肿瘤生长的副干酪乳杆菌l511及其用途
WO2023116283A1 (zh) 一种抗结直肠肿瘤的乳酸肠球菌及其应用
CN110747146A (zh) 具有降解尿酸作用的格氏乳杆菌lg08及其应用
WO2023134203A1 (zh) 脆弱拟杆菌及其两性离子荚膜多糖在制备用于治疗呼吸系统肿瘤药物中的应用
CN109593678B (zh) 长双歧杆菌yh295及其在制备降低腹型肥胖风险产品中的应用
WO2021143621A1 (zh) Anaerostipes sp B2131菌及其在炎症性肠病中的应用
CN114806958B (zh) 胃源性凝结芽孢杆菌bcf-01及其应用
CN114317334B (zh) 一株能够与幽门螺杆菌共聚集的清酒乳杆菌及其应用
CN116083325A (zh) 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用
CN113337440B (zh) 一株唾液乳杆菌mg-587及其应用
CN114854638A (zh) 一株高效表达腺苷脱氨酶缓解结肠炎副干酪乳杆菌
CN111743158B (zh) 一种具有增强免疫功能的益生菌片剂及其制备方法
CN116555074B (zh) 一株短乳杆菌jt1及其在制备降血糖药品中的应用
CN115364125B (zh) 一种携带内皮抑素蛋白的重组长双歧杆菌在制备治疗小鼠结肠炎和结直肠癌的药物中的应用
JP4320408B2 (ja) 胆汁酸結合能を有する新規菌株
CN116426406A (zh) 一种唾液联合乳杆菌dy802及其应用
WO2021169627A1 (zh) Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
CN114588182A (zh) 植物乳杆菌l168辅助索拉非尼治疗肝癌的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22926871

Country of ref document: EP

Kind code of ref document: A1